

Supplementary Table 6. Example TIL marker expression phenotypes from clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab

Phenotype (cells/mm ²)	Fig 5b (monotherapy)		Fig 5c (combination with pembrolizumab)		Supplementary Fig 11 (monotherapy)	
	Pre- treatment	On- treatment	Pre- treatment	On- treatment	Pre- treatment	On- treatment
CD3+	19	241	320	2435	224	2669
CD3+CD4+	14	148	80	642	71	908
CD3+CD8+	0	72	167	1520	137	1449
CD16+CD56+	0	0	36	52	5	33
CD3+CD8+ GRANZYMEB+	0	23	44	421	61	470
PD1+	0	23	146	1074	111	1240
PDL1+	0	62	8042	1108	170	1020
CD3+CD8+HLADR+	0	26	44	1018	36	433
Ki67+	715	833	2707	280	2260	1701
CD3+CD8+Ki67+	0	10	29	80	36	215
CD3+CD4+Ki67+	0	12	7	25	9	84
CD3+CD4+FOXP3+ Ki67+	0	6	7	5	5	39
CD3+CD4+CD134+	0	23	22	79	21	310
CD3+CD8+CD134+	0	2	15	51	8	180